320 related articles for article (PubMed ID: 36775257)
1. The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.
Dibajnia P; Cardenas LM; Lalani AA
Hum Vaccin Immunother; 2023 Dec; 19(1):2178217. PubMed ID: 36775257
[TBL] [Abstract][Full Text] [Related]
2. Treatment Landscape of Renal Cell Carcinoma.
Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
[TBL] [Abstract][Full Text] [Related]
3. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.
Martini A; Fallara G; Pellegrino F; Cirulli GO; Larcher A; Necchi A; Montorsi F; Capitanio U
World J Urol; 2021 May; 39(5):1369-1376. PubMed ID: 33386494
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
6. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis.
Riveros C; Huang E; Ranganathan S; Klaassen Z; Rini B; Wallis CJD; Satkunasivam R
BJU Int; 2023 May; 131(5):553-561. PubMed ID: 36709462
[TBL] [Abstract][Full Text] [Related]
9. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
Cosso F; Roviello G; Nesi G; Shabani S; Spatafora P; Villari D; Catalano M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835654
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K; Berthold DR
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
[TBL] [Abstract][Full Text] [Related]
12. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
Taguchi S; Buti S; Fukuhara H; Otsuka M; Bersanelli M; Morikawa T; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
PLoS One; 2017; 12(2):e0172341. PubMed ID: 28241027
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy for locally advanced renal cell carcinoma.
Alevizakos M; McDermott D
Expert Opin Biol Ther; 2023; 23(12):1265-1275. PubMed ID: 38069655
[TBL] [Abstract][Full Text] [Related]
15. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
Messina C; Zanardi E; Boccardo F
Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
Serzan M; Atkins MB
Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Esteban-Villarrubia J; Romero Ferreiro C; Carril-Ajuria L; Carretero-González A; Iacovelli R; Albiges L; Castellano D; de Velasco G
Urol Oncol; 2023 Sep; 41(9):391.e13-391.e21. PubMed ID: 37331822
[TBL] [Abstract][Full Text] [Related]
18. Perioperative systemic therapy in renal cell carcinoma.
MacPhail C; Wood LA; Thana M
Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
Choueiri M; Tannir N; Jonasch E
Curr Clin Pharmacol; 2011 Aug; 6(3):144-50. PubMed ID: 21827393
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments.
Boyle JJ; Pfail JL; Lichtbroun BJ; Singer EA
JCO Precis Oncol; 2023 Feb; 7():e2200407. PubMed ID: 36724413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
